---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086074"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:48:16.154595+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge

## Summary
- Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).
- EPS $2.44, down 9% reported; comparable +15% excluding $0.56/share discrete litigation accrual.
- Record Q2 premium instrument placements; global premium instrument installed base grew 11% YoY.
- FY2024 guidance updated: revenue $3,885M-$3,945M (6.2-7.8% organic); EPS $10.31-$10.59, down $0.56 at midpoint.
- $62M discrete litigation expense accrual hit operating margin by ~610 bps and EPS by $0.56.

## SEC filing metadata
- accession: 0001104659-24-086074
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/0001104659-24-086074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/tm2420913d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086074
- JSON: https://secwatch.observer/filing/0001104659-24-086074.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.